KINERET 150mg / ml solution for injection medication leaflet

L04AC03 • anakinra • Antineoplastic and immunomodulating agents | Immunosuppressants | Interleukin inhibitors

Anakinra is a biological medication used for the treatment of rheumatoid arthritis and other inflammatory conditions, such as cryopyrin-associated periodic syndrome (CAPS). It is an interleukin-1 (IL-1) receptor antagonist, a cytokine involved in the inflammatory process. By blocking IL-1 action, anakinra reduces inflammation, pain, and joint damage.

Anakinra is administered as a subcutaneous injection, usually once daily, with the dosage varying based on the condition being treated and the patient's response.

Common side effects include injection site reactions, upper respiratory tract infections, headaches, and nausea. In rare cases, severe adverse reactions such as serious infections or neutropenia may occur.

Patients receiving anakinra should undergo regular monitoring for signs of infection and white blood cell counts. Additionally, the medication may interact with other immunosuppressive therapies, requiring caution. Anakinra is a valuable option for managing chronic inflammatory conditions, helping to improve patients' quality of life.